The FDA approved Ogivri, a biosimilar of Roche's Herceptin made by Mylan and Biocon, to treat breast and stomach cancers. A licensing agreement makes the launch date uncertain, according to one analyst; another says the biosimilar will not hit the market until 2019.
FDA approves Herceptin biosimilar, but launch date is uncertain
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.